^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | FLT3 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of FMS-like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia
Published date:
01/05/2021
Excerpt:
FLT3Is demonstrated a significant improvement in OS in patients with relapsed/ refractory AML and a trend towards improvement in OS in newly diagnosed AML patients…All participants were FLT3 mutated in RATIFY, QuANTUM‐R, and ADMIRAL trials...In patients with newly diagnosed AML (n = 1181), pooled HR for OS showed trend towards statistical significance [0·85, 95% CI: 0·72–1·00, P = 0·05] on analysis of three studies.
Source:
Title:
UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
Published date:
05/11/2023
Excerpt:
...the median OS was 34.9 (95% CI, 16.8 to Not Reached [NR]) and 12.7 months (95% CI, 11.6 to 13.9) in the FLT3i and CT group, respectively (log-rank testp<0.001...This study confirmed the benefit of incorporating a FLT3i in the real-life upfront intensive treatment of ND FLT3-mut AML patients.
Source:
Title:
Efficacy Analysis of Different FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients – a Systematic Review and Meta-Analysis
Published date:
11/04/2021
Excerpt:
Most FLT3 inhibitors are effective as monotherapy for the treatment of pts with FLT3-mutated-R/R AML.
DOI:
10.1182/blood-2021-154098
